ENGENE THERAPEUTICS INC
ENGNNASDAQTrading Snapshot
- Day Range
- $1.57 – $1.62
- 52-Week Range
- $1.40 – $12.25
- Volume (shares)
- 46,180.112
- Avg Volume (shares)
- —
- Shares Outstanding
- 67.0M
- Next Earnings
- 2026-12-22
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-2.08
- Dividend Yield
- —
- Dilution (1yr)
- +13.7%
ENGENE THERAPEUTICS INC
ENGN
StockOtter · stockotter.spaceAbout ENGENE THERAPEUTICS INC
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
enGene NASDAQ: ENGN used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse, while community urolo
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript
enGene to Host KOL Webinar on October 15, 2026
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a webinar on Thursday, Octo
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market
enGene Therapeutics remains deeply undervalued, trading below its $3.97/share cash position despite pipeline and execution risks. ENGN's lead asset, detalimogene voraplasmid, faces FDA approval risk due to weak 12-month
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter e